Indeed, CI-1033 was described to have anti-proliferative properties against human epidermal growth factor 2 (HER2)-positive BCCs [54], while DH was described to ameliorate the number of BC stem cells positive for the proliferative marker, aldehyde dehydrogenase, in both HER2+ and TNBC cells [55]. This evidence concerns the gene ERBB2 and breast cancer.